ERBB2 and breast cancer: Based on these data, T-DXd is currently approved for the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the (neo)adjuvant setting and have experienced disease recurrence during or within six months of completing therapy.